[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112017016278A2 - agente preventivo e/ou terapêutico de doença imune - Google Patents

agente preventivo e/ou terapêutico de doença imune

Info

Publication number
BR112017016278A2
BR112017016278A2 BR112017016278-4A BR112017016278A BR112017016278A2 BR 112017016278 A2 BR112017016278 A2 BR 112017016278A2 BR 112017016278 A BR112017016278 A BR 112017016278A BR 112017016278 A2 BR112017016278 A2 BR 112017016278A2
Authority
BR
Brazil
Prior art keywords
immunopathy
prevention
treatment agent
medical treatment
preventive
Prior art date
Application number
BR112017016278-4A
Other languages
English (en)
Japanese (ja)
Other versions
BR112017016278B1 (pt
Inventor
Hosoi Fumihito
Nakachi Yoshinori
KAJIWARA Daisuke
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of BR112017016278A2 publication Critical patent/BR112017016278A2/pt
Publication of BR112017016278B1 publication Critical patent/BR112017016278B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

um agente preventivo e/ou terapêutico para doenças imunes contendo um composto tendo uma atividade inibitória de btk ou um sal deste, como um ingrediente ativo é fornecido. um agente preventivo e/ou terapêutico de doenças imunes, compreendendo um composto representado pela fórmula (i), onde r1 a r3, w, x, y, z, e n representam aqueles como definidos na especificação, ou um sal deste, como um ingrediente ativo.
BR112017016278-4A 2015-01-30 2016-01-29 Uso de um composto com atividade inibitória de btk ou um sal deste para produzir um agente preventivo e/ou terapêutico para a prevenção ou tratamento de uma doença imune BR112017016278B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015017386 2015-01-30
JP2015-017386 2015-01-30
PCT/JP2016/052732 WO2016121953A1 (ja) 2015-01-30 2016-01-29 免疫疾患の予防及び／又は治療剤

Publications (2)

Publication Number Publication Date
BR112017016278A2 true BR112017016278A2 (pt) 2018-03-27
BR112017016278B1 BR112017016278B1 (pt) 2022-05-10

Family

ID=56543555

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016278-4A BR112017016278B1 (pt) 2015-01-30 2016-01-29 Uso de um composto com atividade inibitória de btk ou um sal deste para produzir um agente preventivo e/ou terapêutico para a prevenção ou tratamento de uma doença imune

Country Status (21)

Country Link
US (1) US9782412B2 (pt)
EP (1) EP3120852B1 (pt)
JP (1) JP6093485B2 (pt)
KR (1) KR101858421B1 (pt)
CN (2) CN107206001B (pt)
AU (1) AU2016213030B2 (pt)
BR (1) BR112017016278B1 (pt)
CA (1) CA2975372C (pt)
DK (1) DK3120852T3 (pt)
ES (1) ES2734364T3 (pt)
HU (1) HUE045532T2 (pt)
MX (1) MX2017009863A (pt)
MY (1) MY197518A (pt)
PH (1) PH12017501336A1 (pt)
PL (1) PL3120852T3 (pt)
PT (1) PT3120852T (pt)
RU (1) RU2705154C2 (pt)
SG (1) SG11201704430SA (pt)
TR (1) TR201910158T4 (pt)
TW (1) TWI638817B (pt)
WO (1) WO2016121953A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3115365B1 (en) * 2015-01-30 2018-03-14 Taiho Pharmaceutical Co., Ltd. Novel salt of fused pyrimidine compound and crystal thereof
US20230064254A1 (en) 2019-12-19 2023-03-02 Taiho Pharmaceutical Co., Ltd. Therapeutic agent containing fused pyrimidine compound as active ingredient
CN112209894B (zh) * 2020-10-23 2023-06-06 贵州医科大学 5-芳基取代2-氨基苯并恶唑类衍生物、制备方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336244B (zh) * 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物
KR20150032590A (ko) * 2006-09-13 2015-03-26 다케다 야쿠힌 고교 가부시키가이샤 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도
CA2668286C (en) * 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
WO2009057733A1 (ja) * 2007-10-31 2009-05-07 Santen Pharmaceutical Co., Ltd. 血管新生阻害活性を有する新規インドール誘導体
JP2011526299A (ja) 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド ヘテロアリール化合物およびそれらの使用
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN103857396A (zh) 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
BR112014017749B1 (pt) 2012-01-19 2021-08-03 Taiho Pharmaceutical Co., Ltd. Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
US9573958B2 (en) * 2012-08-31 2017-02-21 Principia Biopharma, Inc. Benzimidazole derivatives as ITK inhibitors
WO2015022926A1 (ja) * 2013-08-12 2015-02-19 大鵬薬品工業株式会社 新規な縮合ピリミジン化合物又はその塩

Also Published As

Publication number Publication date
EP3120852B1 (en) 2019-05-01
JPWO2016121953A1 (ja) 2017-04-27
TR201910158T4 (tr) 2019-07-22
CN107206001B (zh) 2021-09-28
ES2734364T3 (es) 2019-12-05
TW201632526A (zh) 2016-09-16
WO2016121953A1 (ja) 2016-08-04
PH12017501336A1 (en) 2017-12-11
CA2975372C (en) 2020-01-14
CA2975372A1 (en) 2016-08-04
PT3120852T (pt) 2019-07-16
HUE045532T2 (hu) 2020-01-28
CN113768935B (zh) 2024-10-01
AU2016213030A1 (en) 2017-06-22
SG11201704430SA (en) 2017-08-30
CN107206001A (zh) 2017-09-26
TWI638817B (zh) 2018-10-21
RU2017127126A (ru) 2019-03-01
US9782412B2 (en) 2017-10-10
MY197518A (en) 2023-06-19
JP6093485B2 (ja) 2017-03-08
EP3120852A1 (en) 2017-01-25
KR20170083640A (ko) 2017-07-18
CN113768935A (zh) 2021-12-10
KR101858421B1 (ko) 2018-05-15
AU2016213030B2 (en) 2019-01-31
RU2017127126A3 (pt) 2019-03-01
US20170042900A1 (en) 2017-02-16
DK3120852T3 (da) 2019-07-29
RU2705154C2 (ru) 2019-11-05
PL3120852T3 (pl) 2019-09-30
BR112017016278B1 (pt) 2022-05-10
EP3120852A4 (en) 2017-05-24
MX2017009863A (es) 2017-11-15

Similar Documents

Publication Publication Date Title
CO2019008487A2 (es) Compuesto de quinazolina
BR112017014740A2 (pt) composto espiro tricíclico
MD3500564T2 (ro) Inhibitori ai diacilglicerol aciltransferazei 2
PH12017502363A1 (en) Brk inhibitory compound
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
NZ733174A (en) Quinazoline derivatives used to treat hiv
MX2016011468A (es) Inhibidores de calicreína plasmática humana.
BR112014025711A2 (pt) composto, medicamento, e, uso de um composto
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
BR112016017317A8 (pt) composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
BR112012004851B8 (pt) uso de um derivado de tiazol
EA201691570A1 (ru) Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
MX2017016096A (es) Agente antihipertensivo.
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
BR112017016278A2 (pt) agente preventivo e/ou terapêutico de doença imune
MY197042A (en) Compounds
CL2017002229A1 (es) Inhibidores de bace1.
MX2018011539A (es) Tratamiento de dolencias y enfermedades cutaneas asociadas a biopeliculas microbianas.
BR112021000183A8 (pt) Preparação medicinal para uso externo
BR112019002344A2 (pt) composto de 1-fenil-3-carbamoilureia e uso do mesmo
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/01/2016, OBSERVADAS AS CONDICOES LEGAIS